All In Biotech

Drug Trial Radar · NCT06680531

A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Aug 31, 2024

Primary completion

Sep 19, 2024

Study completion Nov 4, 2024

Sponsor

Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Objective: 1\) To evaluate the pharmacodynamic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; 2) To evaluate the pharmacokinetic interaction between YZJ-1139 tablets and Escitalopram oxalate tablets in healthy subjects; To observe the safety of YZJ-1139 tablets taken together with Escitalopram oxalate tablets.

Conditions

  • Insomnia
  • Central Nervous System

Interventions

  • YZJ-1139 tabletsDrug

    YZJ-1139 tablets are administered orally single dose

  • Escitalopram oxalate tabletsDrug

    •oral tablet, QD

  • YZJ-1139 simulated tabletsDrug

    oral tablet, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. saccade eye movement testTime frame: From Day 1 to Day 11
  2. body swing testTime frame: From Day 1 to Day 11
  3. selective reaction time testTime frame: From Day 1 to Day 11
  4. number symbol conversion testTime frame: From Day 1 to Day 11
  5. word memory testTime frame: From Day 1 to Day 11
  6. Maximum Observed Plasma Concentration (Cmax) of YZJ-1139Time frame: From Day 1 to Day 11
  7. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of YZJ-1139Time frame: From Day 1 to Day 11
  8. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of YZJ-1139Time frame: From Day 1 to Day 11
  9. Time of Maximum Observed Plasma Concentration (Tmax) of EntrectinibTime frame: From Day 1 to Day 11
  10. Apparent Terminal Elimination Half-life (t1/2) of EntrectinibTime frame: From Day 1 to Day 11
  11. Apparent Oral Clearance (CL/F) of EntrectinibTime frame: From Day 1 to Day 11
  12. The Apparent Volume of Distribution (Vz/F) of EntrectinibTime frame: From Day 1 to Day 11
  13. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 to Day 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.